S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:IMTX

Immatics (IMTX) Stock Forecast, Price & News

$11.71
-0.14 (-1.18%)
(As of 09/22/2023 ET)
Compare
Today's Range
$11.61
▼
$11.92
50-Day Range
$11.31
▼
$12.62
52-Week Range
$5.90
▼
$13.14
Volume
317,768 shs
Average Volume
290,875 shs
Market Capitalization
$897.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Immatics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.9% Upside
$17.67 Price Target
Short Interest
Bearish
12.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Immatics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.32) to ($1.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

796th out of 962 stocks

Biological Products, Except Diagnostic Industry

125th out of 156 stocks

See Top Rated MarketRank™ Stocks Here

IMTX stock logo

About Immatics (NASDAQ:IMTX) Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTX Price History

IMTX Stock News Headlines

September 22, 2023 | americanbankingnews.com
Leerink Partnrs Analysts Boost Earnings Estimates for Immatics (NASDAQ:IMTX)
September 21, 2023 | finance.yahoo.com
IMTX Oct 2023 10.000 put
September 24, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 11, 2023 | marketwatch.com
Immatics shares rise on Moderna cancer collaboration
September 11, 2023 | bizjournals.com
Moderna enters cancer collaboration with Immatics worth $1.8B
August 27, 2023 | finance.yahoo.com
Those who invested in Immatics (NASDAQ:IMTX) three years ago are up 27%
August 21, 2023 | msn.com
How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%
August 18, 2023 | markets.businessinsider.com
Mizuho Securities Keeps Their Buy Rating on Immatics (IMTX)
September 24, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
August 18, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), CVS Health (CVS)
August 17, 2023 | msn.com
Immatics GAAP EPS of -€0.32, revenue of €22.4M
August 17, 2023 | markets.businessinsider.com
Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX)
August 17, 2023 | finance.yahoo.com
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 10, 2023 | finance.yahoo.com
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
July 24, 2023 | seekingalpha.com
Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203
July 24, 2023 | markets.businessinsider.com
Why Immatics Shares Are Rising Today
July 24, 2023 | seekingalpha.com
Immatics Is Increasingly Becoming Interesting
July 24, 2023 | msn.com
Upcoming Fed Decision, Earnings Fuel Cautiousness, Driving Quiet Premarket Action for US Equity Futures
July 24, 2023 | seekingalpha.com
Immatics climbs 8% on $35M investment by Bristol Myers Squibb
June 25, 2023 | fool.com
Immatics (NASDAQ: IMTX)
May 26, 2023 | finance.yahoo.com
Companies Like Immatics (NASDAQ:IMTX) Are In A Position To Invest In Growth
May 18, 2023 | markets.businessinsider.com
Immatics (IMTX) Gets a Buy from Mizuho Securities
May 17, 2023 | markets.businessinsider.com
Jefferies Keeps Their Buy Rating on Immatics (IMTX)
May 16, 2023 | finance.yahoo.com
Immatics Announces First Quarter 2023 Financial Results and Business Update
May 5, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Immatics (IMTX)
May 3, 2023 | msn.com
Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?
May 2, 2023 | finance.yahoo.com
What's Going On With Immatics Shares Today
See More Headlines
Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Company Calendar

Last Earnings
8/17/2023
Today
9/24/2023
Next Earnings (Estimated)
11/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMTX
CUSIP
N/A
CIK
1809196
Web
www.immatics.com
Phone
4.97072E+12
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+50.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$39.53 million
Net Margins
-93.53%
Pretax Margin
-97.30%
Return on Equity
-41.90%
Return on Assets
-20.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.93
Quick Ratio
2.93

Sales & Book Value

Annual Sales
$182.13 million
Price / Sales
4.93
Cash Flow
$0.61 per share
Price / Cash Flow
19.15
Book Value
$2.93 per share
Price / Book
4.00

Miscellaneous

Outstanding Shares
76,670,000
Free Float
74,141,000
Market Cap
$897.81 million
Optionable
Not Optionable
Beta
0.47
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Harpreet Singh Ph.D. (Age 48)
    CEO, MD, Member of Management Board & Exec. Director
    Comp: $902k
  • Dr. Toni Weinschenk Ph.D. (Age 49)
    Co-Founder & Chief Innovation Officer
  • Mr. Arnd Christ MBA (Age 57)
    Chief Financial Officer
  • Mr. Steffen Walter Ph.D. (Age 46)
    Chief Operations Officer
  • Dr. Carsten Reinhardt M.D. (Age 56)
    Ph.D., Chief Devel. Officer
  • Dr. Rainer Kramer Ph.D. (Age 58)
    Chief Bus. Officer & Site Head Munich
  • Mr. Cedrik M. Britten M.D. (Age 47)
    Chief Medical Officer
  • Dr. Hans-Georg Rammensee Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Mr. Edward A. Sturchio J.D. (Age 47)
    Gen. Counsel & Sec.
  • Ms. Anja Heuer B.Sc.
    Sr. Director Corp. Communications & Head of Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













IMTX Stock - Frequently Asked Questions

Should I buy or sell Immatics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings or view top-rated stocks.

What is Immatics' stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price targets for Immatics' shares. Their IMTX share price forecasts range from $12.00 to $25.00. On average, they anticipate the company's share price to reach $17.67 in the next year. This suggests a possible upside of 50.9% from the stock's current price.
View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts.

How have IMTX shares performed in 2023?

Immatics' stock was trading at $8.71 at the start of the year. Since then, IMTX shares have increased by 34.4% and is now trading at $11.71.
View the best growth stocks for 2023 here.

When is Immatics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 16th 2023.
View our IMTX earnings forecast.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) released its quarterly earnings results on Thursday, August, 17th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.01. The firm earned $24.33 million during the quarter, compared to analysts' expectations of $18.97 million. Immatics had a negative trailing twelve-month return on equity of 41.90% and a negative net margin of 93.53%.

What ETFs hold Immatics' stock?

ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

What is Immatics' stock symbol?

Immatics trades on the NASDAQ under the ticker symbol "IMTX."

Who are Immatics' major shareholders?

Immatics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Rock Springs Capital Management LP (3.31%), 683 Capital Management LLC (1.76%), Woodline Partners LP (1.58%), Artisan Partners Limited Partnership (0.92%), Sphera Funds Management LTD. (0.80%) and Samsara BioCapital LLC (0.52%).

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immatics' stock price today?

One share of IMTX stock can currently be purchased for approximately $11.71.

How much money does Immatics make?

Immatics (NASDAQ:IMTX) has a market capitalization of $897.81 million and generates $182.13 million in revenue each year. The company earns $39.53 million in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Immatics have?

The company employs 210 workers across the globe.

How can I contact Immatics?

Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 4.97072E+12.

This page (NASDAQ:IMTX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -